Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.

[1]  P. Lu,et al.  Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae. , 2020, International journal of antimicrobial agents.

[2]  P. Nordmann,et al.  Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  K. Bush,et al.  Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. , 2019, The Journal of antimicrobial chemotherapy.

[4]  Ya-Ting Chang,et al.  Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012-2015 , 2019, Infection and drug resistance.

[5]  A. Antoniadou,et al.  In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016 , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  M. Souli,et al.  Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens , 2019, Expert opinion on drug metabolism & toxicology.

[7]  M. Motyl,et al.  Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. , 2018, Journal of global antimicrobial resistance.

[8]  W. Ko,et al.  In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) , 2018, Infection and drug resistance.

[9]  N. Martin,et al.  β-lactam/β-lactamase inhibitor combinations: an update. , 2018, MedChemComm.

[10]  M. Motyl,et al.  In Vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection Models , 2018, Antimicrobial Agents and Chemotherapy.

[11]  Yi-Tsung Lin,et al.  Carbapenem Nonsusceptible Klebsiella pneumoniae in Taiwan: Dissemination and Increasing Resistance of Carbapenemase Producers During 2012–2015 , 2018, Scientific Reports.

[12]  Suzannah M. Schmidt-Malan,et al.  In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli , 2018, Antimicrobial Agents and Chemotherapy.

[13]  F. Codjoe,et al.  Carbapenem Resistance: A Review , 2017, Medical sciences.

[14]  J. Karlowsky,et al.  Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations , 2017, Drugs.

[15]  David J. Milne,et al.  Development of a Manufacturing Route to Avibactam, a β-Lactamase Inhibitor , 2016 .

[16]  D. Venskutonis,et al.  Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection , 2016, Antimicrobial Agents and Chemotherapy.

[17]  G. Meletis,et al.  Carbapenem resistance: overview of the problem and future perspectives , 2016, Therapeutic advances in infectious disease.

[18]  D. Landman,et al.  Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City , 2015, Antimicrobial Agents and Chemotherapy.

[19]  N. Woodford,et al.  NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. , 2014, The Journal of antimicrobial chemotherapy.

[20]  J. Hermes,et al.  Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. , 2014, Bioorganic & medicinal chemistry letters.

[21]  Yee-Chun Chen,et al.  First Report of blaIMP-8 in Raoultella planticola , 2013, Antimicrobial Agents and Chemotherapy.

[22]  D. Livermore,et al.  Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. , 2013, The Journal of antimicrobial chemotherapy.